Veradermics (MANE) EPS (Weighted Average and Diluted) (2025 - 2026)
Veradermics posted quarterly EPS (Weighted Average and Diluted) of -$1.32 for Q1 2026, up 93.33% year-on-year from -$0.68 in Q1 2025, and up 93.33% on a QoQ basis from -$19.79 in Q1 2025.
Veradermics (MANE) has 2 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.32 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 93.33% year-over-year to -$1.32; the trailing twelve-month figure through Mar 2026 stood at -$1.96 (changed N/A YoY), and the FY2025 full-year result was -$111.91, down 202.05% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$1.32, up from -$19.79 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$1.32 in Q1 2026 and bottomed at -$19.79 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Veradermics | 2.29 Bn | 2.29 Bn | - | -1.32 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.32 |
| Mar 31, 2025 | -19.79 |